Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5 portion of a target gene relative to the 3 region of the target gene. The average expression of the 5 portion of the target gene is compared with the average expression of the 3 portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.

Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5 portion of a target gene relative to the 3 region of the target gene. The average expression of the 5 portion of the target gene is compared with the average expression of the 3 portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.

Provided herein are methods and compositions to detect MET exon 14 skipping using RT-PCR, and methods of treating individuals with MET exon 14 deleted cancers.

Provided herein are methods and compositions to detect MET exon 14 skipping using RT-PCR, and methods of treating individuals with MET exon 14 deleted cancers.

Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5 portion of a target gene relative to the 3 region of the target gene. The average expression of the 5 portion of the target gene is compared with the average expression of the 3 portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.

Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5 portion of a target gene relative to the 3 region of the target gene. The average expression of the 5 portion of the target gene is compared with the average expression of the 3 portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.

The present invention relates to a method for screening a compound for Parkinson's disease treatment, comprising contacting a cell having a DJ-1 gene containing a c.192G>C mutation with a compound of interest, and testing whether said compound of interest prevents skipping of exon 3 of said DJ-1 gene, thereby identifying said compound as candidate for Parkinson's disease treatment. The present invention further relates to a compound which prevents skipping of exon 3 of the DJ-1 gene for use in a method of treatment of Parkinson's disease. The present invention further relates to a pharmaceutical composition comprising one or more compounds which prevents skipping of exon 3 of the DJ-1 gene for use in a method of treatment of Parkinson's disease.

The present invention relates to a method for screening a compound for Parkinson's disease treatment, comprising contacting a cell having a DJ-1 gene containing a c.192G>C mutation with a compound of interest, and testing whether said compound of interest prevents skipping of exon 3 of said DJ-1 gene, thereby identifying said compound as candidate for Parkinson's disease treatment. The present invention further relates to a compound which prevents skipping of exon 3 of the DJ-1 gene for use in a method of treatment of Parkinson's disease. The present invention further relates to a pharmaceutical composition comprising one or more compounds which prevents skipping of exon 3 of the DJ-1 gene for use in a method of treatment of Parkinson's disease.

The present disclosure relates to the fields of a method a kit for molecular diagnostics and genomics. More particularly, this disclosure relates to a method and a kit fir detecting a DNA fragment joining event or distinguishing an alternative splicing event. The present disclosure also relates to a method for administering a subject with proper treatment by steps of determining the risk of a particular cancer type or genotype.

The present disclosure relates to the fields of a method a kit for molecular diagnostics and genomics. More particularly, this disclosure relates to a method and a kit fir detecting a DNA fragment joining event or distinguishing an alternative splicing event. The present disclosure also relates to a method for administering a subject with proper treatment by steps of determining the risk of a particular cancer type or genotype.